Literature DB >> 23751955

Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita.

Shahinaz M Gadalla1, Carmem Sales-Bonfim, Jeanette Carreras, Blanche P Alter, Joseph H Antin, Mouhab Ayas, Prasad Bodhi, Jeffrey Davis, Stella M Davies, Eric Deconinck, H Joachim Deeg, Reggie E Duerst, Anders Fasth, Ardeshir Ghavamzadeh, Neelam Giri, Frederick D Goldman, E Anders Kolb, Robert Krance, Joanne Kurtzberg, Wing H Leung, Alok Srivastava, Reuven Or, Carol M Richman, Philip S Rosenberg, Jose Sanchez de Toledo Codina, Shalini Shenoy, Gerard Socié, Jakub Tolar, Kirsten M Williams, Mary Eapen, Sharon A Savage.   

Abstract

We describe outcomes after allogeneic transplantation in 34 patients with dyskeratosis congenita who underwent transplantation between 1981 and 2009. The median age at transplantation was 13 years (range, 2 to 35). Approximately 50% of transplantations were from related donors. Bone marrow was the predominant source of stem cells (24 of 34). The day-28 probability of neutrophil recovery was 73% and the day-100 platelet recovery was 72%. The day-100 probability of grade II to IV acute GVHD and the 3-year probability of chronic graft-versus-host disease were 24% and 37%, respectively. The 10-year probability of survival was 30%; 14 patients were alive at last follow-up. Ten deaths occurred within 4 months from transplantation because of graft failure (n = 6) or other transplantation-related complications; 9 of these patients had undergone transplantation from mismatched related or from unrelated donors. Another 10 deaths occurred after 4 months; 6 of them occurred more than 5 years after transplantation, and 4 of these were attributed to pulmonary failure. Transplantation regimen intensity and transplantations from mismatched related or unrelated donors were associated with early mortality. Transplantation of grafts from HLA-matched siblings with cyclophosphamide-containing nonradiation regimens was associated with early low toxicity. Late mortality was attributed mainly to pulmonary complications and likely related to the underlying disease.
Copyright © 2013 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Allogeneic transplantation; Dyskeratosis congenita; Long-term survival; Pulmonary toxicity

Mesh:

Year:  2013        PMID: 23751955      PMCID: PMC3736557          DOI: 10.1016/j.bbmt.2013.05.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  23 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita.

Authors:  Mohamad M Al-Rahawan; Neelam Giri; Blanche P Alter
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case Report and systematic literature review.

Authors:  Neelam Giri; Rees Lee; Albert Faro; Charles B Huddleston; Frances V White; Blanche P Alter; Sharon A Savage
Journal:  BMC Blood Disord       Date:  2011-06-15

4.  Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita.

Authors:  Nobuhiro Nishio; Yoshiyuki Takahashi; Haruhiko Ohashi; Sayoko Doisaki; Hideki Muramatsu; Asahito Hama; Akira Shimada; Hiroshi Yagasaki; Seiji Kojima
Journal:  Pediatr Transplant       Date:  2010-12-22

5.  Unusual complications after bone marrow transplantation for dyskeratosis congenita.

Authors:  V Rocha; A Devergie; G Socié; P Ribaud; H Espérou; N Parquet; E Gluckman
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

Review 6.  Cancer in dyskeratosis congenita.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Philip S Rosenberg
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

7.  Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment.

Authors:  Zhenyu Ju; Hong Jiang; Maike Jaworski; Chozhavendan Rathinam; Anne Gompf; Christoph Klein; Andreas Trumpp; K Lenhard Rudolph
Journal:  Nat Med       Date:  2007-05-07       Impact factor: 53.440

8.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.

Authors:  Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

9.  Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation.

Authors:  Josu de la Fuente; Inderjeet Dokal
Journal:  Pediatr Transplant       Date:  2007-09

10.  Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.

Authors:  Blanche P Alter; Gabriela M Baerlocher; Sharon A Savage; Stephen J Chanock; Babette B Weksler; Judith P Willner; June A Peters; Neelam Giri; Peter M Lansdorp
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

View more
  39 in total

Review 1.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

Review 2.  Neonatal manifestations of inherited bone marrow failure syndromes.

Authors:  Payal P Khincha; Sharon A Savage
Journal:  Semin Fetal Neonatal Med       Date:  2015-12-24       Impact factor: 3.926

3.  Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.

Authors:  M Brown; D Myers; N Shreve; R Rahmetullah; M Radhi
Journal:  Bone Marrow Transplant       Date:  2016-01-25       Impact factor: 5.483

Review 4.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 5.  Genetic predisposition syndromes: when should they be considered in the work-up of MDS?

Authors:  Daria V Babushok; Monica Bessler
Journal:  Best Pract Res Clin Haematol       Date:  2014-11-12       Impact factor: 3.020

Review 6.  Extrahematopoietic manifestations of the short telomere syndromes.

Authors:  Kristen E Schratz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  Telomere length in hematopoietic cell transplant.

Authors:  Shahinaz M Gadalla
Journal:  Blood       Date:  2020-12-24       Impact factor: 22.113

Review 8.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

Review 9.  Bone marrow failure and the telomeropathies.

Authors:  Danielle M Townsley; Bogdan Dumitriu; Neal S Young
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

10.  Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.

Authors:  Siobán B Keel; Angela Scott; Marilyn Sanchez-Bonilla; Phoenix A Ho; Suleyman Gulsuner; Colin C Pritchard; Janis L Abkowitz; Mary-Claire King; Tom Walsh; Akiko Shimamura
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.